As proof‐of‐concept of this type of molecular surgery for lung cancer, we propose to use CRISPR/Cas9 to repair or destroy the EGFR gene in EGFR‐mutant NSCLC, as shown in Fig 1, with examples from the most common primary and secondary mutations. Here, EGFR is linked to non-small cell lung carcinoma.